Interim data for the 2023-2024 flu season shows that the vaccine has protected all age groups
As one of the sites in the U.S. Influenza Vaccine Effectiveness (Flu VE) network for more than 13 years, Kaiser Permanente Washington Health Research Institute (KPWHRI) conducts research during flu season that helps the CDC (Centers for Disease Control and Prevention) understand the effectiveness of licensed flu vaccines for different age groups and types of influenza.
In February, the CDC published the interim results of that effectiveness research for the 2023-2024 flu season. Senior Investigator Karen Wernli, PhD, is a coauthor on the report, which found that, so far, flu vaccines have substantially reduced the risk of flu-related medical visits and hospitalizations for all age groups.
“It’s very exciting to see this data showing that the vaccines are doing a good job of protecting people,” said Wernli. “Annual flu vaccination is one of the best ways to avoid getting the flu and to prevent serious complications.”
